Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Valcyte Expected To Erode Ganciclovir Scripts After Spring Launch

Executive Summary

Roche anticipates that Valcyte (valganciclovir) will begin to erode oral Cytovene (ganciclovir) prescriptions for the treatment of cytomegalovirus retinitis in AIDS patients following spring launch.
Advertisement

Related Content

Cytovene I.V. Shortage Will Be Resolved by Second Quarter, Roche Says
Cytovene I.V. Shortage Will Be Resolved by Second Quarter, Roche Says
Roche Valganciclovir Phase IV Studies Should Investigate HAART Effect
Roche Valganciclovir Phase IV Studies Should Investigate HAART Effect
Advertisement
UsernamePublicRestriction

Register

PS037603

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel